Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 11, 2001 - Issue 10
Submit an article Journal homepage
88
Views
0
CrossRef citations to date
0
Altmetric
Miscellaneous

Antisense oligonucleotides as drugs for HIV treatment

U Galderisi
,
M Cipollaro
&
A Cascino
Pages 1605-1611 | Published online: 25 Feb 2005

Bibliography

  • AGRAWAL S, IYER RP: Modified oligonucleotides as therapeutic and diagnostic agents. Curr. Opin. Biotechnol. (1995) 6:12–19.
  • •Examples of modified ODNs.
  • GALDERISI U, CASCINO A, A: Antisense oligonucleotides as therapeutics agents. I Cell Physiol. (1999) 181:251–257.
  • WAGNER RW: The state of art in antisense research. Nat. Med. (1995) 1:1116–1118.
  • WAGNER RW, FLANAGAN WM: Antisense technology and prospects for therapy of viral infections and cancer. Mai Med. Today (1997) 3:31–38.
  • •Deals with antisense open problems in clinical trials.
  • AGRAWAL S: Antisense oligonucleotides: clinical trial. Trends Biotechnol. (1996) 14:376–387.
  • •Problems and solutions for antisense clinical trials.
  • PRASEUTH D, GUIEYSSE AL, HELENE: Triple helix formation and the antigene strategy for sequence-specific control of gene expression. Biochem. Biophys. Acta. (1999) 1489(1):181–206.
  • GALDERISI U, DI BERNARDO G, MELONE MAB et al.: Antisense inhibitory effects: a comparison between 3'-partial and full phosphorothioate antisense oligonucleotides. j Cell Biochem. (1999) 74:31–37.
  • STEIN CA: Does antisense exist? Nature Med. (1995) 1:119–121.
  • BELTINGER C, SARAGOVI HU, SMITH RM et al..: Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. j Clin. Invest. (1995) 95:1814–1823.
  • ••In depth studies on ODN uptake.
  • AGRAWAL S, TENSAMANI J, W, TANG J: of antisense nucleotides.Pharmacokinet. (1995) 28:7–16.
  • COSSUM PA, SASMOR H, DELLINGER: Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide ISIS2105 after intra-venous administration to rats. Pharmacol. Esp. Ther. (1993) 267:1181–1190.
  • GALBRAITH WM, HOBSON WC, GICLAS PC, SCHEEHTER PI, AGRAWAL S: Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res. Dev (1994) 4:201–206.
  • •Side effects of antisense therapy.
  • IVERSEN PL, ZHU S, MEYER A, ZON G: Cellular uptake and sub-cellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. (1992) 2:211–222.
  • RAYNAUD FI, ORR RIVI, GODDARD PM et al.: Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bc1-2, after intravenous administration or continuous subcutaneous infusion to mice. j Pharmacol. Exp. Ther. (1997) 281:420–427.
  • ZHANG R, DIASIO RB, LU Z et al.: Pharmacokinetics and tissue disposition in rats of an oligodeoxynucleotide phosphorothioate (GEM91) developed as a therapeutic agent for human immunodeficiency virus Type 1. Biochem. Pharmacol. (1995) 49:929–939.
  • ZHANG R, LU Z, ZHANG X, DIASIO RB et al.: In vivo stability, disposition and metabolism of a 'hybrid' oligonucleotide phosphorothioate in rats. Biochem. Pharmacol. (1995) 50:545–556.
  • AGRAWAL S, IKEUCHI T, SUN D etal.: Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotides and their analogues. Proc. Nati Acad. Sri. USA. (1989) 86(20):7790–7794.
  • INDER M, NIKUNJ S: Gene therapy - promises, problems and prospect. Nature (1997) 389:239–242.
  • LEE RJ, HUANG L: Lipidic vector systems for gene transfer. Grit. Rev Ther. Dug Carrier Syst. (1997) 14(2):173–206.
  • BRADBURY J: Antisense drugs move towards the clinic. Lancet (1997) 349:259.
  • JUNKER U, BAKER J, KALFOGLOU CS, VERES G, KANESHIMA H, BOHNLEIN E: Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus Type 1. AIDS Res. Hum. Retroviruses (1997) 13:1395–1402.
  • LEEDS JM, HENRY SP, BISTNER S, SCHERRILL S, WILLIAMS K, LEVIN AA: Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab. Dispos. (1998) 26:670–675.
  • •One of the few studies on monkeys.
  • TOMASSELLI AG, HEINRIKSON RL: Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochem. Biophys. Acta. (2000) 1477(1-2):189–214.
  • JOHNSON SC, GERBER JG: Advances in HIV/AIDS therapy. Adv. Intern. Med. (2000) 45:1–40.
  • MURPHY EL, COLLIER AC, KALISH LA et al.: Highly active antiretroviral Therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. (2001) 135(1):17–26.
  • ZAMECNIK PC, GOODCHILD J, TAGUCHI Y, SARIN PS: Inhibition of replication and expression of human T-cell lymphotropic virus Type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Nati Acad. Sri. USA. (1986) 83(12):4143–4146.
  • GOODCHILD J, AGRAWAL S, CIVEIRA MP, SARIN PS, SUN D, ZAMECNIK PC. Inhibition of human immunodeficiency replication by antisense. Proc Nati Acad Li USA. (1988) 85(15):5507–5511.
  • SARIN PS, AGRAWAL S, CIVEIRA MP, GOOD CHILD J, IKEUCHI T, ZAMECNIK PC: Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc. Natl. Acad. Li. USA. (1988) 85(20):7448–7451.
  • MATSUKURA M, SHINOZUKA K, ZON G et al.: Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl. Acad. Sci USA. (1987) 84(20:7706–7710.
  • SHIBAHARA S, MUKAI S, MORISAWA H, NAKASHIMA H, KOBAYASHI S, YAMAMOTO N: Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives. Nucleic Acids Res. (1989) 17(1):239–252.
  • MORI K, BOIZIAU C, CAZENAVE C et al. Phosphoroselenoate oligodeoxy-nucleotides: synthesis, physico-chemical characterization, anti-sense inhibitory properties and anti-HIV activity. Nucleic Adds Res. (1989) 17(20):8207–8219.
  • STEVENSON M, IVERSEN PL: of human immunodeficiency virus Type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotides. j. Gen Viral. (1989) 70 (10):2673–2682.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.